Sanofi $SNY Shares Bought by Price T Rowe Associates Inc. MD

Key Points

• Price T Rowe Associates Inc. MD increased its stake in Sanofi by 1.8%, holding over 11 million shares valued at approximately $612 million.
• Multiple institutions significantly boosted their positions in Sanofi, including Mirae Asset Global Investments, which grew its stake by 124%.
• Sanofi's latest earnings report showed a miss in EPS estimates, reporting $0.90 compared to a consensus of $0.96, despite a revenue of $11.34 billion exceeding expectations.

Price T Rowe Associates Inc. MD raised its position in Sanofi (NASDAQ:SNY - Free Report) by 1.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,036,878 shares of the company's stock after acquiring an additional 193,196 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.44% of Sanofi worth $612,106,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its position in Sanofi by 124.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company's stock valued at $1,344,000 after acquiring an additional 13,358 shares in the last quarter. Axxcess Wealth Management LLC grew its position in Sanofi by 130.5% in the first quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company's stock valued at $568,000 after acquiring an additional 5,794 shares in the last quarter. Ballentine Partners LLC grew its position in Sanofi by 68.7% in the first quarter. Ballentine Partners LLC now owns 26,063 shares of the company's stock valued at $1,445,000 after acquiring an additional 10,617 shares in the last quarter. Sowell Financial Services LLC acquired a new stake in Sanofi in the first quarter valued at approximately $328,000. Finally, Farther Finance Advisors LLC grew its position in shares of Sanofi by 66.2% during the first quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company's stock worth $338,000 after buying an additional 2,476 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on SNY. Guggenheim reissued a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Morgan Stanley set a $56.00 price target on shares of Sanofi in a research report on Monday, June 2nd. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Sanofi in a research report on Tuesday, August 5th. Finally, Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Three investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Sanofi currently has a consensus rating of "Buy" and a consensus target price of $62.00.

Sanofi Stock Performance

Sanofi stock opened at $51.35 on Friday. The company has a market cap of $126.09 billion, a PE ratio of 12.34, a P/E/G ratio of 1.21 and a beta of 0.48. The company has a fifty day moving average price of $48.62 and a two-hundred day moving average price of $51.73. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. Sanofi has a 12 month low of $44.73 and a 12 month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The business had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business's revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.73 EPS. Research analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.